Background Chimeric antigen receptor T (CAR-T) cell therapy has made significant
advances for hematological malignancies but encounters obstacles in the treatment of solid …

Background Patients with relapsed/refractory T-cell malignancies have limited treatment
options. The use of chimeric antigen receptor (CAR)-T cell therapy for T-cell malignancies is …

Cancer-associated fibroblasts play a crucial role within the tumor microenvironment.
However, a comprehensive characterization of CAF in colorectal cancer (CRC) is still …

Background Chimeric antigen receptor-engineered T cell (CAR-T) therapy has shown
promising potential for anti-cancer treatment. However, for pancreatic ductal …

SBT6290 is a novel product candidate comprised of a selective TLR8 agonist conjugated to
a Nectin4-specific monoclonal antibody, designed for systemic delivery and tumor-localized …

Chimeric antigen receptor T cell (CAR-T) therapy is novel tumor immunotherapy that
enables autologous T to express synthetic receptors to specifically recognize the surface …

Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective cancer treatment,
such as for hematological malignancies, however its effectiveness as an approach to treat …

Claudin 18.2 (CLDN18. 2)-targeting chimeric antigen receptor (CAR)-modified T cells are
one of the few cell therapies currently producing an impressive therapeutic effect in treating …

In 2013, cancer immunotherapy led the annual breakthroughs in Science. In fact,
immunotherapy is one of the hotspots in cancer therapy, and can date back to the Coley …

Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment
of hematological malignant tumors; however, its efficacy towards solid cancer remains …